Jiangsu Leili Motor Corp Ltd

During the Jiangsu leg of the “Dynamic China Survey Tour,” reporters from The Paper found that a group of niche industry leaders are upgrading their capabilities through cross-sector breakthroughs, reflecting the iterative evolution logic of Chinese manufacturing. Jiangsu Leili Motor has moved from home appliance motors into the new energy vehicle and robotics sectors, with related business revenue growing from tens of millions of yuan to over 900 million yuan in just a few years. Famsun, leveraging its expertise in agricultural and livestock equipment processes, has made its pet food equipment number one in domestic market share and achieved import substitution. Cell and gene therapy company Cellbri Bio has slashed the production cost of autologous cell therapy from 300,000 to 500,000 yuan to around 100,000 yuan, making cell and gene therapy more accessible. Wei Liurong, an expert at the China Academy of Information and Communications Technology, said that the systematic expansion of leading enterprises into adjacent tracks has become an industrial phenomenon, and its essence is the concentrated release of China’s core manufacturing technologies, industrial ecosystem, and scenario advantages.

Jiangsu Leili has established a complete layout across the embodied intelligence supply chain, covering core components, motion control assemblies, intelligent control, and motion bases. The company plans to focus this year on deploying dexterous hand components on factory assembly lines. Last year, its revenue exceeded 4 billion yuan for the first time, and its core robot components have entered the supply chains of multiple domestic and international robot body manufacturers, module makers, and dexterous hand enterprises. Revenue from the robotics projects of its holding subsidiary, Dingzhi Technology, surged 687.23 percent year-on-year in 2025. Zhongke Lingxi has developed dexterous hands using three major technical routes: linkage-driven, cable-driven, and direct-drive. All core components are domestically produced, and at equivalent performance, prices are 30 to 50 percent lower than comparable products. The company also noted that the current price of a complete humanoid robot exceeds 1 million yuan, with the dexterous hand accounting for nearly 20 percent of the total cost. High cost is the biggest barrier to large-scale adoption, while insufficient generalization capability is another major challenge. Jiangsu Leili positions itself as a supplier of core hardware components and will not venture into robot body manufacturing for the time being.